Medical Industry Feature

Medical Industry Feature highlights topics brought to you by makers of products and services in the medical industry.

Medical Industry Feature is a science podcast hosted by ReachMD, with 39 episodes on record and a Required Pod Score of 80.

ReachMD hosts Medical Industry Feature, a science show with 39 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  Medical Industry Feature

  Vitreous Hemorrhage Following PVD: Who Needs Surgery?

  Sep 22, 202613 min

  Host: Barton Lynn Blackorby, MD Guest: Kyle Davis Kovacs, MD Guest: Matthew Starr, MD How aggressively should you manage a vitreous hemorrhage after a PVD when you can't see the retina underneath it? Barton Blackorby, MD, moderates a discussion with Matt Starr, MD, and Kyle Kovacs, MD, about a study published in Ophthalmology by Hasbolat et al examining 366 patients with PVD-related vitreous hemorrhage initially managed with observation. The panel discusses how exam technique and B-scan reliance may affect detachment detection rates, debates follow-up intervals given that most retinal detachments in the study occurred within the first 3 weeks, and shares their own thresholds for moving to early vitrectomy versus continued observation, including how they counsel patients eager for faster visual recovery.

  ListenShow Notes
• 

  Medical Industry Feature

  Groundbreaking Gene Therapy Restores Natural Hearing for Genetic Deafness

  Sep 16, 202619 min

  Guest: Lawrence Lustig, M.D. On this episode of Advances in Care, Erin Welsh speaks with Dr. Lawrence Lustig, otolaryngologist-in-chief at NewYork-Presbyterian and Columbia. Dr. Lustig has spent decades working to advance various interventions to treat genetic deafness and after years of research, his team was the first to show that gene therapies could be effective at reversing hearing loss in mouse models. Dr. Lustig focused his initial study on otoferlin, a gene that is missing in people with a rare form of genetic deafness, and how to safely deliver it back to patients. Starting with mouse models and solving for the uniquely large size of the gene, they discovered that packaging otoferlin with an adeno-associated virus and injecting it into the ear completely reversed deafness. From there, they began the process of trialing this approach in humans at NewYork-Presbyterian and Columbia. The trials were successful, leading to natural hearing restoration in most patients, and in April 2026 the work culminated with an FDA approval of the first ever gene therapy for genetic deafness based on the research pushed forward by Dr. Lustig and his team. Dr. Lustig’s team has trialed the therapy in patients across a range of ages, from six years old to …

  ListenShow Notes
• 

  Medical Industry Feature

  Does Preoperative Anti-VEGF Change Outcomes in Non-Tractional Vitreous Hemorrhage?

  Sep 2, 20266 min

  What happens when vitreous hemorrhage (VH) secondary to non-tractional PDR doesn't clear on its own? And does preoperative anti-VEGF actually change surgical outcomes? Maria Berrocal, MD, speaks with Sumit Sharma, MD, about a retrospective case series of 360 patients who underwent vitrectomy for non-clearing VH without tractional elements, examining whether preoperative anti-VEGF injection affects the risk of postoperative rebleeding, when to consider repeat vitrectomy, and how both physicians approach these cases in their own practices.

  ListenShow Notes
• 

  Medical Industry Feature

  The Positive Impact of Electroconvulsive Therapy for Severe Psychiatric Illness

  Aug 23, 202617 min

  Guest: Leonardo Lopez, M.D. On this episode of Advances in Care, Erin Welsh is joined by Dr. Leonardo Lopez, a psychiatrist at NewYork-Presbyterian and vice chair for inpatient services in the Department of Psychiatry at Weill Cornell Medicine. Dr. Lopez and his team are at the forefront of electroconvulsive therapy (ECT) and have built one of the largest programs of its kind in the country dedicated to treating severe psychiatric illness through this revolutionary method. Though it is one of the most effective therapies available for certain psychiatric conditions like treatment resistant depression and schizophrenia, ECT isn’t widely adopted or accessible. However, Dr. Lopez hopes to change that. In the episode, he describes the history of this treatment, how it has evolved since its inception to become one of the safest procedures done under general anesthesia, and the dramatic response rates. ECT works by restructuring neurotransmitter release and promoting neuronal growth. Patients with conditions like psychotic depression and catatonia can sometimes see upwards of 90-95% response rates. To illustrate the power of ECT, Dr. Lopez shares the story of a pediatric patient who was referred to his team after being diagnosed with catatonia caused by another condition. Although the other condition was treated, the …

  ListenShow Notes
• 

  Medical Industry Feature

  R/R LBCL: A Practical Guide to CAR T Referral and Coordination

  Aug 19, 202611 min

  Guest: Loretta J. Nastoupil, MD Guest: Manali Kamdar, MD CAR T cell therapy has been established as a standard-of-care option in the second-line setting for appropriate relapsed/refractory patients with large B-cell lymphoma (LBCL). 1 Some outcomes data suggest more favorable outcomes when CAR T is used in the second-line setting compared with subsequent lines of therapy. 2,3 That’s why it’s important to not wait to refer and to consult with a CAR T specialist for all on-label patients—early evaluation gives patients the best opportunity to optimize outcomes. 3,4 In this episode of Project Oncology , Drs. Loretta Nastoupil and Manali Kamdar sit down to discuss the evolving role of CAR T-cell therapy in relapsed or refractory LBCL, including patient eligibility, referral timing, and care coordination between referring and treatment centers. Dr. Nastoupil is an oncologist with Southwest Oncology and CommonSpirit Mercy in Durango, Colorado. Dr. Kamdar is a Professor of Medicine and Clinical Director of the Lymphoma Program at the University of Colorado School of Medicine and the UCHealth Blood Disorders and Cell Therapies Center in Aurora, Colorado. Dr. Nastoupil and Dr. Kamdar were compensated by Bristol Myers Squibb for their participation. References: Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ® ) for B-Cell Lymphomas V.4.2026. © …

  ListenShow Notes

Recent guests on Medical Industry Feature. Study who booked and why before you pitch.

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.